1-11 of 11
Richard M. Neve
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5949: The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC

Free
Yan Wang, Allison Roberts, Philamer Calses, Richard M. Neve, Jocelyn Staunton, Kevin R. Webster
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5949.
https://doi.org/10.1158/1538-7445.AM2024-5949
Published: 22 March 2024
View articletitled, Abstract 5949: The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC
Journal Articles

Abstract 5948: FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance

Free
Yan Wang, Richard M. Neve, Jocelyn Staunton, Kevin R. Webster
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5948.
https://doi.org/10.1158/1538-7445.AM2024-5948
Published: 22 March 2024
View articletitled, Abstract 5948: FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance
Journal Articles

Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C

Free
Snahel Patel, Barun Bhhatarai, Philamer Calses, Daniel Erlanson, Robert Everley, Susan Fong, Phil Gerken, Johannes C. Hermann, Tiep Le, Li-kai Liu, Evan McMahon, Richard M. Neve, Tony Phan, Allison Roberts, Mikayla Shanafelt, Sophie Siemsgluess, Jocelyn Staunton, Yan Wang, Weiru Wang, Monika Williams, Kevin R. Webster
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1142.
https://doi.org/10.1158/1538-7445.AM2023-1142
Published: 04 April 2023
View articletitled, Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C
Journal Articles

Abstract 3601: Discovery of novel dual-acting KRASG12C inhibitors that target both the active and inactive forms of the protein

Free
Philamer Calses, Sam Clark, Jacob Corpuz, Susan Fong, Phil Gerkin, Mohammad Hekmatnejad, Evan McMahon, Megan Murray, Truc Nguyen, Tony Phan, Allison Roberts, Phillip Schwartz, Mikayla Shanafelt, Hiroko Tanaka, Jennifer Tomczyk, John Widen, Monika Williams, John Eksterowicz, Daniel Erlanson, Marie Evangelista, Johannes Hermann, Richard M. Neve, Snahel Patel, Kevin R. Webster
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3601.
https://doi.org/10.1158/1538-7445.AM2022-3601
Published: 15 June 2022
View articletitled, Abstract 3601: Discovery of novel dual-acting KRASG12C inhibitors that target both the active and inactive forms of the protein
Journal Articles

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

Free
Catherine Wilson, Xiaofen Ye, Thinh Pham, Eva Lin, Sara Chan, Erin McNamara, Richard M. Neve, Lisa Belmont, Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi, Jeff Settleman
Journal: Cancer Research
Series: Author Choice
Cancer Res (2014) 74 (20): 5878–5890.
https://doi.org/10.1158/0008-5472.CAN-14-1009
Published: 14 October 2014
View articletitled, AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Open the PDF for AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract 693: AXL tyrosine kinase inhibition selectively sensitizes mesenchymal cancer cells to antimitotic agents

Free
Catherine Wilson, Thinh Pham, Xiaofen Ye, Eva Lin, Sara Chan, Erin McNamara, Richard M. Neve, Lisa Belmont, Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi, Jeff Settleman
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 693.
https://doi.org/10.1158/1538-7445.AM2014-693
Published: 01 October 2014
View articletitled, Abstract 693: AXL tyrosine kinase inhibition selectively sensitizes mesenchymal cancer cells to antimitotic agents
Journal Articles

Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Free
Genee Y. Lee, Peter M. Haverty, Li Li, Noelyn M. Kljavin, Richard Bourgon, James Lee, Howard Stern, Zora Modrusan, Somasekar Seshagiri, Zemin Zhang, David Davis, David Stokoe, Jeffrey Settleman, Frederic J. de Sauvage, Richard M. Neve
Journal: Cancer Research
Cancer Res (2014) 74 (11): 3114–3126.
https://doi.org/10.1158/0008-5472.CAN-13-2683
Published: 29 May 2014
View articletitled, Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
Open the PDF for Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes in another window
Includes: Supplementary data
Journal Articles

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

Free
Olga K. Mirzoeva, Debopriya Das, Laura M. Heiser, Sanchita Bhattacharya, Doris Siwak, Rina Gendelman, Nora Bayani, Nicholas J. Wang, Richard M. Neve, Yinghui Guan, Zhi Hu, Zachary Knight, Heidi S. Feiler, Philippe Gascard, Bahram Parvin, Paul T. Spellman, Kevan M. Shokat, Andrew J. Wyrobek, Mina J. Bissell, Frank McCormick, Wen-Lin Kuo, Gordon B. Mills, Joe W. Gray, W. Michael Korn
Journal: Cancer Research
Cancer Res (2009) 69 (2): 565–572.
https://doi.org/10.1158/0008-5472.CAN-08-3389
Published: 15 January 2009
View articletitled, Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Open the PDF for Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition in another window
Includes: Supplementary data
Journal Articles

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

Free
Katherine Stemke-Hale, Ana Maria Gonzalez-Angulo, Ana Lluch, Richard M. Neve, Wen-Lin Kuo, Michael Davies, Mark Carey, Zhi Hu, Yinghui Guan, Aysegul Sahin, W. Fraser Symmans, Lajos Pusztai, Laura K. Nolden, Hugo Horlings, Katrien Berns, Mien-Chie Hung, Marc J. van de Vijver, Vicente Valero, Joe W. Gray, René Bernards, Gordon B. Mills, Bryan T. Hennessy
Journal: Cancer Research
Cancer Res (2008) 68 (15): 6084–6091.
https://doi.org/10.1158/0008-5472.CAN-07-6854
Published: 01 August 2008
View articletitled, An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
Open the PDF for An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A system to identify and validate baseline and biologic response predictors in breast cancer

Free
Richard M. Neve, Koei Chin, Sandy Devries, Jennifer Yeh, Jean-Philippe Coppe, Jane Fridyland, Laura Clark, Nora Bayani, Frances Tong, Terry Speed, Joe W. Gray
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 793.
Published: 15 April 2006
View articletitled, A system to identify and validate baseline and biologic response predictors in breast cancer
Journal Articles

EGFR-dependent reciprocal expression of EPHA2 and ERBB3 is associated with breast cancer risk.

Free
Richard M. Neve, Madhu Macrae, Frederick L. Baehner, Karen Chew, Dan Moore, Frank McCormick, Joe W. Gray
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1345–1346.
Published: 15 April 2006
View articletitled, EGFR-dependent reciprocal expression of EPHA2 and ERBB3 is associated with breast cancer risk.